Compare PESI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | INBX |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | 307 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.3M | 1.5B |
| IPO Year | 1996 | 2024 |
| Metric | PESI | INBX |
|---|---|---|
| Price | $17.39 | $108.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 267.6K | ★ 322.5K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $642,000.00 | ★ $1,300,000.00 |
| Revenue This Year | $34.62 | N/A |
| Revenue Next Year | $77.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $8.58 | $26.20 |
| 52 Week High | $21.32 | $155.29 |
| Indicator | PESI | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 49.61 |
| Support Level | $14.18 | $96.60 |
| Resistance Level | $19.02 | $153.14 |
| Average True Range (ATR) | 0.76 | 8.01 |
| MACD | -0.17 | -2.50 |
| Stochastic Oscillator | 5.18 | 38.52 |
Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.